Amneal Releases 2022 Environmental, Social and Governance Report
16 June 2023 - - US-based pharmaceuticals company Amneal Pharmaceuticals, Inc. (NYSE: AMRX) has released its third annual Environmental, Social and Governance Report, the company said.

This 2022 report provides a look at our progress across our ESG focus areas, including updates to our people data and sustainability programs.

New this year, the report is mapped to the United Nations Sustainable Development Goals (UN SDGs) and highlights our contributions in support of Goal 3: Good Health and Well-Being.

With a primary focus on addressing critical health needs via innovative and affordable medicines, Amneal is responsibly living its purpose of making healthy possible for patients, communities, and the planet.

Key 2022 ESG Achievements

Affordability and Accessibility: Saving patients over USD 10bn in the U.S with generic and biosimilars medicines.

Hosting its first-ever global employee volunteering event focused on health and hygiene kit-making and celebrating our 10-year partnership (20+ m doses of Amneal medicine donated to date) providing medicines to underserved and uninsured patients with Dispensary of Hope.

Environmental Stewardship: Creating and convening a Global Environmental Working Group to address the climate crisis and working toward aligning its disclosures with the Task Force on Climate-Related Financial.

Creating an initial manual Greenhouse Gas emissions inventory, onboarding a carbon accounting vendor and initiating the rollout of a global Environmental, Health and Safety system.

Diversity, Equity, Inclusion and Belonging: Launching an Employee Resource Group pilot program in the US to provide a platform for employees to connect and collaborate around shared interests and identities.

Conducting an insightful workshop on the importance of diversity, equity, inclusion, and belonging for senior leaders, and launching our Amneal Listens employee listening and engagement strategy

Good Governance: Appointing its second female Board member with an extensive track record in quality, regulatory and policy, aligned with its priority on fostering a Board that reflects expanded experiences and perspectives.

Completing its second board diversity survey, aligning our Global Supplier Code of Conduct with the United Nations Guiding Principles and including a Sustainability Accounting Standards Board index aligned with the biotechnology and Pharmaceuticals Standard in our 2022 ESG report.

Looking ahead to 2023, Amneal's growing commitment to delivering value aligned with the United Nations Sustainable Development Goal 3: Good Health and Well-Being, demonstrates our desire to be an even more important partner in the pursuit of a healthier global future.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated global pharmaceuticals company.